semaglutide approved for mash 🎉Exciting news that is now FDA (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% FDA Approves Wegovy® as First

The most commonly reported effects include nausea, changes in bowel habits, mild gastrointestinal discomfort, and temporary appetite fluctuations

J Biol Chem 193:265275

More importantly, cardiovascular and renal outcome studies have demonstrated that GLP-1RAs and related multi-receptor agonists not only lower body weight and blood glucose but also significantly reduce the risk of major adverse cardiovascular events (MACE) and the worsening of renal function

No, GHK-Cu peptide works differently and therefore, can complement Botox and fillers by improving overall skin quality and longevity of results

Weekly timing should remain consistent, with injections administered on the same day each week

BPC-157 is one of the most exciting regenerative tools we have in holistic veterinary medicine